abrdn Life Sciences Investors Overview
Pro stress-test →abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. that invests in stocks of companies operating in the life sciences sector, including biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The Fund seeks long-term capital appreciation.
Strategic Profile
Pro stress-test →The fund primarily invests in growth stocks of small cap companies. Effective close of business on October 27, 2023, abrdn, Inc. assumed responsibility for the management of the fund, formerly known as Tekla Life Sciences Investors. The fund provides exposure to emerging life sciences companies with potential for significant growth in biotechnology products and services driven by aging demographics and adoption of new medical innovations.
Competitive Landscape
Pro stress-test →Related closed-end healthcare and life sciences funds in the abrdn family include abrdn Healthcare Investors (HQH), abrdn Healthcare Opportunities Fund (THQ), and abrdn World Healthcare Fund (THW). The fund competes with other life sciences-focused mutual funds and ETFs serving institutional and retail investors seeking exposure to biotech and healthcare innovation.
Industry Context
abrdn Life Sciences Investors operates in Asset Management - Closed-End Mutual Funds.
Key facts
Founded: 1992 · Headquarters: Philadelphia, US